Acute Myeloid Leukemia - Heat Map and Analysis

ReportsWorldwide has announced the addition of a new report title Acute Myeloid Leukemia - Heat Map and Analysis to its growing collection of premium market research reports.

Acute Myeloid Leukemia (AML) is a rare but serious disease, and the most common leukemia suffered by adults. The first-line treatment in eligible patients is almost always intensive chemotherapy. Despite strong initial remission rates, relapse is common, and AML has the lowest five-year survival rate of all leukemias, at 25%. Efforts have been made to introduce novel therapies to the AML market, but its treatment has changed little in the last 40 years. However, a number of products are currently in late-stage development for the treatment of AML, both before and after the induction of remission and relapse.

Scope of the Report:

- What are the clinical characteristics of currently approved therapies for AML, in terms of specific safety and efficacy parameters?

- What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them?

- A number of pipeline therapies are in the late-stage pipeline for the post-relapse setting, but do they have sufficient differentiating characteristics to make a strong impact on the market and clinic?

- Which line of therapy in AML stands to benefit most from the current late-stage pipeline?

- Will current pipeline targeted therapies be able to successfully enter the market for AML, or will chemotherapy remain the treatment modality of choice in this indication for the foreseeable future?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6861

Reasons to buy

- Understand the current clinical landscape by considering the treatment options available for each patient segment.

- Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials.

- Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy.

- Understand the relative strengths and weaknesses of the studies used to gather these data.

- Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks.

- Assess your own pipeline programs in light of these benchmarks, in order to optimally position them and maximize uptake by clinicians.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/acute-myeloid-leukemia-heat-map-and-analysis

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.